Immunogenic hla-a2 supermotif-restricted peptides
CA 2432995 C · Owner: Sidney, John · Inventors: Southwood, Scott; Grey, Howard M.; Sette, Alessandro
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods to design vaccines which are effective in individuals bearing A2 supertype alleles are described. Single amino acid substitution analogs of known A2-supertype binding peptides, and large peptide libraries were utilized to rigorously define the peptide binding specificities of A2-supertype molecules. While each molecule was noted to have unique preferences large , overlaps in specificity were found. The presence of the hydrophobic and aliphatic residues L, I, V, M, A, T, and Q in positon 2 of peptide ligands was commonly tolerated by A2-supertype molecules. L I, V, M, A, and T were , tolerated at the C-terminus. While examination of secondary influences on peptide binding …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 29, 2002 and granted July 26, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.